Trials, tricks and transparency: How disclosure rules affect clinical knowledge

Journal of Health Economics

Volumn 28, Issue 6, 2009, Pages 1141-1153

  Dahm, Matthias ^a   González, Paula ^b   Porteiro, Nicolás ^b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

Clinical trials; Incentives; Pharmaceutical firms; Registries; Results databases; Scientific knowledge; Strategic information transmission

Indexed keywords

DATABASE; GEOGRAPHICAL KNOWLEDGE; INCENTIVE; PHARMACEUTICAL INDUSTRY; PROVENANCE TRIAL; THEORETICAL STUDY;

ACCESS TO INFORMATION; ARTICLE; CLINICAL RESEARCH; DATA BASE; DECISION MAKING; DRUG INDUSTRY; GOVERNMENT REGULATION; INFORMATION DISSEMINATION; MANDATORY REPORTING; POSTMARKETING SURVEILLANCE; REGISTER; RESEARCH ETHICS; VOLUNTARY REPORTING;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG INDUSTRY; HUMANS; INFORMATION DISSEMINATION; REGISTRIES;

EID: 70549086886     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2009.08.004     Document Type: Article

References (49)

1. Avorn J. Dangerous deception-hiding the evidence of adverse drug effects. The New England Journal of Medicine 355 21 (2006) 2169-2171
2. Azoulay P. Do pharmaceutical sales respond to scientific evidence?. Journal of Economics and Management Strategy 11 4 (2002) 551-594
3. Bennedsen M., and Feldmann S. Informational lobbying and political contributions. Journal of Public Economics 90 (2006) 631-656
4. Berenson A. Cardiologists Question Delay of Data on 2 Drugs (2007), The New York Times November 21
5. Brekke K.R., and Kuhn M. Direct to consumer advertising in pharmaceutical markets. Journal of Health Economics 25 (2006) 102-130
6. Caruso D. A Challenge to Gene Theory, a Tougher Look at Biotech (2007), The New York Times July 1
7. Congressional Budget Office (2006). Research and Development in the Pharmaceutical Industry, available at: http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf [accessed January 4, 2008].
8. Chalmers I. Unbiased, relevant, and reliable assessments in health care: important progress during the past century, but plenty of scope for doing better?. British Medical Journal 317 (1998) 1167-1168
9. Chan A.-W., Hróbjartsson A., Haahr M.T., Gøtzsche P.T., and Altman D.G. Empirical evidence for selective reporting of outcomes in randomized trials. The Journal of the American Medical Association 291 (2004) 2457-2465
10. Committee on Clinical Trial Registries (2006). Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Report, The National Academies Press, available at: http://www.nap.edu/catalog.php?record_id=11561 [accessed January 4, 2008].
11. Couzin J. Drug research: legislators propose a registry to track clinical trials from start to finish. Science 305 (2004) 1695
12. Couzin, J., 2004. Momentum Builds for Clinical Trial Registration, ScienceNow, September 10, 2004. available at: http://sciencenow.sciencemag.org/cgi/content/full/2004/910/1 [accessed January 4, 2008].
13. Couzin J. Clinical trials: facing criticism, industry offers to share data. Science 307 (2005) 189
14. Curfman G.D., Morrissey S., Drazen, J.M., 2005. Expression of concern: Bombardier et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine, 353, 2813-14.. Curfman G.D., Morrissey S., Drazen, J.M., 2000. Expression of concern: Bombardier et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine, 243, 1520-28.
15. Dahm M., and Porteiro N. Informational lobbying under the shadow of political pressure. Social Choice and Welfare 30 4 (2008) 531-559
16. Davidoff F., De Angelis C.D., Drazen J.M., Hoey J., Højgaard L., Horton R., Kotzin S., Nicholls M.G., Nylenna M., John A., Overbeke P.M., Sox H.D., Van Der Weyden M.B., and Wilkes M.S. Sponsorship, authorship and accountability. The New England Journal of Medicine 345 11 (2001) 825-826
17. De Angelis C.D., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R., Kotzin S., Laine C., Marusic A., Overbeke A.J., Schroeder T.V., Sox H.C., and Van Der Weyden M.B. Clinical trial registration: a statement from the International Committee of Medical. Journal Annals of Internal Medicine 141 (2004) 477-478
18. De Angelis C.D., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R., Kotzin S., Laine C., Marusic A., Overbeke A.J., Schroeder T.V., Sox H.C., and Van Der Weyden M.B. Is this clinical trial fully registered?: a statement from the International Committee of Medical Journal, International Committee of Medical Journal. The Journal of the American Medical Association 293 (2005) 2927-2929
19. Dickersin, K., 2008. Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain, available at: http://dida.library.ucsf.edu/tid/oxx18r10 [accessed July 23, 2009].
20. Drazen M.J., Morrissey S., and Curfman G.D. Open clinical trials. The New England Journal of Medicine 357 17 (2007) 1756-1757
21. Folland S., Goodman A.C., and Stano M. The Economics of Health and Health Care (2004), Pearson Prentice Hall, New Jersey
22. Glasser S.P., Salas M., and Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. The Journal of Clinical Pharmacology 47 (2007) 1074-1086
23. Grabowski H., and Vernon J. Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics 13 (1994) 383-406
24. Grabowski H., Vernon J., and DiMasi J.A. Returns on research and development for 1990s. New Drug Introductions Pharmacoeconomics 20 3 (2002) 11-29
25. Gulmezoglu A., Pang T., Horton R., and Dickersin K. WHO facilitates international collaboration in setting standards for clinical trial registration. Lancet 365 (2005) 1829-1831
26. Harris G., and Koli E. Lucrative Drug, Danger Signals and the FDA (2005), The New York Times June 10
27. Harris G. Heart Surgery Drug Pulled from Market (2007), The New York Times November 6
28. Horton R., and Smith R. Time to register randomised trials. British Medical Journal 319 (1999) 865-866
29. Krimsky S. Conflict of interest and cost-effectiveness analysis. The Journal of the American Medical Association 282 15 (1999) 1474-1475
30. Laine C., Horton R., De Angelis C.D., Drazen J.M., Frizelle F.A., Godlee F., Haug C., Hébert P.C., Kotzin S., Marusic A., Sahni P., Schroeder T.V., Sox H.C., Van Der Weyden M.B., and Verheug F.W.A. Clinical trial registration: looking back and moving ahead International Committee of Medical Journal. The New England Journal of Medicine 356 26 (2007) 2734-2736
31. Lewis, T.R., Reichman, J.H., So, A.D., 2007. The Case for Public Funding and Public Oversight of Clinical Trials, The Economists' Voice, 4 (1), Article 3. Available at: http://www.bepress.com/ev/vol4/iss1/art3.
32. Milgrom P. Good news and bad news: representation theorems and applications. Bell Journal of Economics 12 (1981) 380-391
33. Milgrom P., and Roberts J. Relying on the information of interested parties. Rand Journal of Economics 17 1 (1986) 18-32
34. Palmisano, S., 2005. The information puzzle. Newsweek, Issue December 2
35. Pouvourville G. Risk-sharing agreements for innovative drugs. A new solution to old problems. European Journal of Health Economics 7 (2006) 155-157
36. Prescrire International (2007). A look back at pharmaceuticals in 2006: aggressive advertising cannot hide the absence of therapeutic advances, Prescrire International, 16, 80-86.
37. Research and Markets (2007). Phase IV Clinical Trials: Post-Marketing Study, Management Structure, Strategy & Benchmarks, available at: http://www.researchandmarkets.com/reports/368249 [accessed January 4, 2008].
38. Rising K., Bacchetti P., and Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation. PLoS Medicine 5 11 (2008) 1561-1570
39. Rockhold F.W., and Krall R.L. Trial summaries on results databases and journal publication. Lancet 367 (2006) 1635-1636
40. Sekeres M., Gold J.L., Chan A.-W., Lexchin J., Moher D., Van Laethem M.L.P., Maskalyk J., Ferris L., Taback N., and Rochon P.A. Poor reporting of scientific leadership information in clinical trial registries. PLoS ONE 3 2 (2008) 1-6
41. Schmalensee R. A model of promotional competition in oligopoly. Review of Economic Studies 43 3 (1976) 493-507
42. Simes R.J. Publication bias: the case for an international registry of clinical trials. Journal of Clinical Oncology 4 (1986) 1529-1541
43. Simes, R.J., 1997. Controlled clinical trials, in: Kerr, Taylor, Heard (Eds.), Handbook of Public Health Methods, pp. 120-136.
44. Simes R.J. Clinical trials and real-world medicine. The Medical Journal of Australia 177 21 (2002) 407-408
45. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials 29 (2008) 109-113
46. Tufts Center for the Study of Drug Development (2004). FDA requested postmarketing studies in 73% of recent new drug approvals, Impact Report 6 (4).
47. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine 358 3 (2008) 252-260
48. Vlahakes G.J. The value of phase 4 clinical testing. The New England Journal of Medicine 354 4 (2006) 413-414
49. Zarin D.H., Tse T., and Ide N.C. Trial registration at clinicaltrials.gov between May and October. The New England Journal of Medicine 353 26 (2005) 2779-2787